USE OF ANTITHROMBIN IN THE TREATMENT OF PRE-ECLAMPSIA

• US 20140206617A1
• Filed: 03/12/2013
• Published: 07/24/2014
• Est. Priority Date: 03/12/2012
• Status: Abandoned Application

• Current Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Original Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Inventors: Frieling, Johan, Lowry, Simon
• Application Number:
  US14/239,869
• Publication Number:
  US 20140206617A1
• Time in Patent Office: Days
• US Class Current: 514/14.7
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

In one aspect, the disclosure provides methods for the treatment of pre-eclampsia and severe pre-eclampsia comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.

Claims

1. A method of treating pre-eclampsia in a subject, the method comprising:

administering to a subject having pre-eclampsia a therapeutically effective amount of antithrombin to treat the pre-eclampsia.

2. The method of claim 1, wherein the pre-eclampsia is severe pre-eclampsia.

3. The method of claim 1 or claim 2, wherein the subject is at less than 24 weeks of pregnancy.

4. The method of claim 1 or claim 2, wherein the subject is at between 24 weeks and 28 weeks of pregnancy.

5. The method of claim 1 or claim 2, wherein the subject is at between 28 weeks and 32 weeks of pregnancy.

6. The method of claim 1 or claim 2, wherein the subject is at between 28 weeks and 34 weeks of pregnancy.

7. The method of claim 1 or claim 2, wherein the subject is at over 34 weeks of pregnancy.

8. The method of any one of claims 1-7, wherein the antithrombin has a high mannose glycosylation pattern.

9. The method of any one of claims 1-8, wherein the antithrombin comprises GalNac (N-acetylgalactosamine).

10. The method of any one of claims 1-9, wherein the antithrombin has a fucose-GlcNAc glycosylation pattern.

11. The method of any one of claims 1-10, wherein the antithrombin is transgenically produced antithrombin.

12. The method of claim 11, wherein the antithrombin is transgenically produced in a goat.

13. The method of any one of claims 1-12, wherein the antithrombin is ATryn®

.

14. The method of any one of claims 1-13, wherein the antithrombin is administered at a dose of 1500 units per day.

15. The method of any one of claims 1-13, wherein the antithrombin is administered at a dose of 3000 units per day.

16. The method of any one of claims 1-13, wherein the antithrombin is administered at a dose of 12,000 units per day.

17. The method of any one of claims 1-16, wherein the antithrombin is administered through continuous infusion.

18. The method of any one of claims 1-16, wherein the antithrombin is administered as a bolus.

19. The method of any one of claims 1-13, wherein the antithrombin is administered at a dose of 3500 units twice daily by bolus infusion.

20. The method of any one of claims 1-13, wherein the antithrombin is administered at a dose of 10,500 units daily by continuous infusion.

21. The method of any one of claims 1-13, wherein the antithrombin is administered at a dose of 12,000 units daily by continuous infusion.